HIPECT4: multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intra-peritoneal chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal carcinoma


Por: Arjona-Sanchez A, Barrios P, Boldo-Roda E, Camps B, Carrasco-Campos J, Martin V, Garcia-Fadrique A, Gutierrez-Calvo A, Morales R, Ortega-Perez G, Perez-Viejo E, Prada-Villaverde A, Torres-Melero J, Vicente E, Villarejo-Campos P, Sanchez-Hidalgo J, Casado-Adam A, Garcia-Martin R, Medina M, Caro T, Villar C, Aranda E, Cano-Osuna M, Diaz-Lopez C, Torres-Tordera E, Briceno-Delgado F, Rufian-Pena S

Publicada: 13 feb 2018
Resumen:
Background: Local relapse and peritoneal carcinomatosis (PC) for pT4 colon cancer is estimated in 15,6% and 36,7% for 12 months and 36 months from surgical resection respectively, achieving a 5 years overall survival of 6%. There are promising results using prophylactic HIPEC in this group of patients, and it is estimated that up to 26% of all T4 colon cancer could benefit from this treatment with a minimal morbidity. Adjuvant HIPEC is effective to avoid the possibility of peritoneal seeding after surgical resection. Taking into account these results and the cumulative experience in HIPEC use, we will lead a randomized controlled trial to determine the effectiveness and safety of adjuvant treatment with HIPEC vs. standard treatment in patients with colon cancer at high risk of peritoneal recurrence (pT4). Methods/Design: The aim of this study is to determine the effectiveness and safety of adjuvant HIPEC in preventing the development of PC in patients with colon cancer with a high risk of peritoneal recurrence (cT4). This study will be carried out in 15 Spanish HIPEC centres. Eligible for inclusion are patients who underwent curative resection for cT4NxM0 stage colon cancer. After resection of the primary tumour, 200 patients will be randomized to adjuvant HIPEC followed by routine adjuvant systemic chemotherapy in the experimental arm, or to systemic chemotherapy only in the control arm. Adjuvant HIPEC will be performed simultaneously after the primary resection. Mitomycin C will be used as chemotherapeutic agent, for 60 min at 42-43 degrees C. Primary endpoint is loco-regional control (LC) in months and the rate of loco-regional control (%LC) at 12 months and 36 months after resection. Discussion: We assumed that adjuvant HIPEC will reduce the expected absolute risk of peritoneal recurrence from 36% to 18% at 36 months for T4 colon-rectal carcinoma.

Filiaciones:
Arjona-Sanchez A:
 Hosp Univ Reina Sofia, Unit Oncol & Pancreat Surg, Menendez Pidal Av, Cordoba 14004, Spain

 Hosp Univ Reina Sofia, IMIBIC, CIBERehd, Cordoba, Spain

Barrios P:
 Hosp St Joan Despi Moises Broggi, Consorci Sanitari Integral, Unit Surg, Barcelona, Spain

Boldo-Roda E:
 Hosp Prov Castellon, Unit Surg, Castellon de La Plana, Spain

Camps B:
 Univ Valencia, Hosp Clin, Unit Oncol Surg, Valencia, Spain

Carrasco-Campos J:
 Hosp Reg Univ Malaga, Unit Surg, Malaga, Spain

Martin V:
 Hosp Univ Nuestra Senora de la Candelaria, Unit Peritoneal Oncol Surg & Colorectal Surg, Tenerife, Spain

Garcia-Fadrique A:
 Inst Valenciano Oncol, Dept Surg, Valencia, Spain

Gutierrez-Calvo A:
 Hosp Principe Asturias, Surg Dept, Unit Peritoneal Oncol Surg, Madrid, Spain

Morales R:
 Hosp Son Spaces, Unit Oncol & Pancreat Surg, Palma De Mallorca, Spain

Ortega-Perez G:
 MD Anderson Canc Ctr, Madrid, Spain

Perez-Viejo E:
 Hosp Univ Fuenlabrada, Unit Oncol Surg, Madrid, Spain

Prada-Villaverde A:
 Hosp Univ Infanta Cristina, Unit Surg, Badajoz, Spain

Torres-Melero J:
 Hosp Torrecardenas, Unit Surg, Almeria, Spain

Vicente E:
 San Pablo Univ, Clara Campal Oncol Ctr, Sanchinarro Univ Hosp, Dept Surg,CEU, Madrid, Spain

Villarejo-Campos P:
 Hosp Univ Ciudad Real, Unit Surg, Ciudad Real, Spain

Sanchez-Hidalgo J:
 Hosp Univ Reina Sofia, Unit Oncol & Pancreat Surg, Menendez Pidal Av, Cordoba 14004, Spain

 Hosp Univ Reina Sofia, IMIBIC, CIBERehd, Cordoba, Spain

Casado-Adam A:
 Hosp Univ Reina Sofia, Unit Oncol & Pancreat Surg, Menendez Pidal Av, Cordoba 14004, Spain

 Hosp Univ Reina Sofia, IMIBIC, CIBERehd, Cordoba, Spain

Garcia-Martin R:
 Hosp Univ Reina Sofia, Unit Oncol & Pancreat Surg, Menendez Pidal Av, Cordoba 14004, Spain

Medina M:
 Hosp Univ Reina Sofia, IMIBIC, CIBERehd, Cordoba, Spain

 Hosp Univ Reina Sofia, Unit Pathol, Cordoba, Spain

Caro T:
 Hosp Univ Reina Sofia, IMIBIC, CIBERehd, Cordoba, Spain

 Hosp Univ Reina Sofia, Unit Pathol, Cordoba, Spain

Villar C:
 Hosp Univ Reina Sofia, IMIBIC, CIBERehd, Cordoba, Spain

 Hosp Univ Reina Sofia, Unit Pathol, Cordoba, Spain

Aranda E:
 Hosp Univ Reina Sofia, IMIBIC, CIBERehd, Cordoba, Spain

 Hosp Univ Reina Sofia, Unit Oncol, Cordoba, Spain

Cano-Osuna M:
 Hosp Univ Reina Sofia, IMIBIC, CIBERehd, Cordoba, Spain

 Hosp Univ Reina Sofia, Unit Oncol, Cordoba, Spain

Diaz-Lopez C:
 Hosp Univ Reina Sofia, IMIBIC, CIBERehd, Cordoba, Spain

 Hosp Univ Reina Sofia, Unit Colorectal Surg, Cordoba, Spain

Torres-Tordera E:
 Hosp Univ Reina Sofia, Unit Colorectal Surg, Cordoba, Spain

Briceno-Delgado F:
 Hosp Univ Reina Sofia, Unit Oncol & Pancreat Surg, Menendez Pidal Av, Cordoba 14004, Spain

 Hosp Univ Reina Sofia, IMIBIC, CIBERehd, Cordoba, Spain

Rufian-Pena S:
 Hosp Univ Reina Sofia, Unit Oncol & Pancreat Surg, Menendez Pidal Av, Cordoba 14004, Spain

 Hosp Univ Reina Sofia, IMIBIC, CIBERehd, Cordoba, Spain
ISSN: 14712407





Bmc Cancer
Editorial
BIOMED CENTRAL LTD, 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 18 Número:
Páginas:
WOS Id: 000425516500008
ID de PubMed: 29439668

MÉTRICAS